Ocugen's OCU400 Wins Bahamas Provisional Approval and Priority Designation for Retinitis Pigmentosa
核心洞察
Ocugen's investigational modifier gene therapy OCU400 received provisional approval and priority designation from The Bahamas' Longevity and Regenerative Therapies Board for retinitis pigmentosa (搜索).
Ocugen plans to supply OCU400 through an expanded access program and aims to treat the first retinitis pigmentosa (搜索) patient within 90 days of full LARTA Board approval.
OCU400 is in Phase 3 development for a broad retinitis pigmentosa (搜索) indication with enrollment complete and topline data expected in the first quarter of 2027.
Ocugen's investigational modifier gene therapy OCU400 has received provisional approval and priority designation from the Longevity and Regenerative Therapies Board (LARTA Board) in The Bahamas for the treatment of retinitis pigmentosa (搜索) (RP), the company announced.
Under the approval, Ocugen plans to provide OCU400 through an expanded access program (EAP), with the goal of treating the first RP patient within 90 days following full approval by the LARTA Board. The LARTA Priority Designation recognizes the scientific and clinical potential of a therapy addressing significant unmet medical needs and provides enhanced regulatory engagement and expedited coordination toward full approval and patient access.
Ocugen said its partnership with the LARTA Board is intended to expand global access to OCU400 while developing a commercial pricing approach supported by cost-effectiveness considerations for a one-time treatment of RP.
A Modifier Gene Approach Beyond Single Mutations
OCU400 is currently being evaluated in Phase 3 clinical development for a broad RP indication covering early- to late-stage disease as well as pediatric and adult patients. The Phase 3 trial has completed enrollment, with topline results expected in the first quarter of 2027.
The therapy is designed to address retinal diseases associated with mutations in more than 100 genes. Unlike conventional gene therapies that target individual gene mutations, OCU400 is a modifier gene therapy based on the nuclear hormone receptor gene NR2E3 (搜索). It is designed to restore balance across multiple gene networks involved in retinal function, including photoreceptor development, metabolism, inflammation and cell survival.
RP is a genetic disease that can progressively damage the retina and can eventually cause blindness.
Regulatory Status and Filing Plans
OCU400 has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation from the U.S. FDA, as well as Orphan Medicinal Product Designation from the European Medicines Agency. In Europe, the therapy has also been classified as an Advanced Therapy Medicinal Product. In the UK, it remains an investigational Phase 3 therapy.
Ocugen expects topline Phase 3 data for OCU400 in the first quarter of 2027 and plans to submit a Biologics License Application (BLA) in the second quarter of 2027. The company is working with the LARTA Board toward full approval and expanded access to OCU400 in The Bahamas.
Outside the United States, Ocugen has licensed its rights to OCU400 to Kwangdong Pharmaceutical (搜索) in South Korea and is currently negotiating an exclusive licensing agreement covering the Middle East and North Africa.
Broader Ophthalmology Pipeline
Ocugen has two other late-stage eye-disease programs. OCU410ST is in a Phase 2/3 study for Stargardt disease (搜索), an inherited condition that causes progressive vision loss, with topline results expected in the second quarter of 2027. OCU410 is another gene therapy targeting geographic atrophy caused by dry age-related macular degeneration (搜索) (AMD). The first patient was dosed in its global Phase 3 study earlier this month, with a potential regulatory filing targeted for 2028.
To support the development and filing of these therapies, Ocugen expects its cash runway to extend through 2028, after ending the June quarter with $100.1 million in cash and cash equivalents following a convertible-note financing.